Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

BRAFTOVI

ENCORAFENIB

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview BRAFTOVI is listed in Drugs@FDA under application 210496 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ENCORAFENIB Form and strength CAPSULE;ORAL - 50MG Sponsor ARRAY BIOPHARMA INC Submission history Latest submission status date: 2026-02-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRAFTOVI is listed in Drugs@FDA under application 210496 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ENCORAFENIB Form and strength CAPSULE;ORAL - 50MG Sponsor ARRAY BIOPHARMA INC Submission history Latest submission status date: 2026-02-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.